Pharmacyclics
Eric Yan is a highly experienced professional in the field of pharmaceutics, currently serving as a Senior Scientist at Pharmacyclics, an AbbVie Company, since October 2014. Prior to this role, Eric was a Scientist within the same organization and gained valuable experience as a Research Associate at Novartis from 2010 to 2014. Eric began a career in research at the University of Chicago, working as staff from 2008 to 2010. Educational qualifications include a Master of Science in Pharmaceutics from the University of Illinois Chicago, a Bachelor of Science in Pharmaceutics from Beijing Medical University, and another Master of Science in Pharmacy from the National University of Singapore.
This person is not in any teams
This person is not in any offices
Pharmacyclics
1 followers
Pharmacyclics is committed to the development and commercialization of novel therapies intended to improve the quality and duration of life and to resolve serious unmet medical needs for cancer patients. Pharmacyclics is a wholly-owned subsidiary of AbbVie (NYSE:ABBV), a global, research-based biopharmaceutical company. Oncology is a key therapeutic area for AbbVie, with a portfolio consisting of three marketed products and a pipeline containing multiple promising new molecules that are being studied in more than 200 clinical trials for over 20 different types of cancer. More than 1,200 Pharmacyclics and AbbVie research scientists, clinicians, marketing, operations and corporate professionals work in the San Francisco Bay Area. They combine their expertise in immuno-oncology, stem cells, and cell-signaling with their knowledge of bispecific antibodies, antibody-drug conjugates (ADCs), and covalent-inhibitor technologies to discover and develop novel cancer treatments. Together, we are striving to outsmart cancer.